Tradestie Institutional Equity Comparison Engine

DGNX vs RXRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RXRX Overall Edge

RXRX Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) driven by superior Growth & Margin, Momentum & Technical while DGNX counters with relative strength in Options & Structure. Fundamentally, DGNX trades at N/M Forward P/E with -546.3% operating margin (+3.3% YoY revenue) versus RXRX at N/M Forward P/E and -734.2% operating margin (+258.5% YoY). In options structure, DGNX sits in BREAKDOWN (51st %ile IV; Dealer Gamma Walls on Pro) against RXRX sits in BREAKDOWN (61st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DGNX N/M vs RXRX N/M Fwd P/E
Growth & Margin Winner RXRX
Op Margin -546.3% vs -734.2% ยท YoY +3.3% vs +258.5%
Momentum & Technical Winner RXRX
1Y -91.3% vs -32.9% ยท 52W Pos 4% vs 6%
Options & Structure Winner DGNX
BREAKDOWN (51st %ile IV) vs BREAKDOWN (61st %ile IV)
DGNX NASDAQ
Diginex Limited Ordinary Shares
Services-Computer Processing & Data Preparation
$1.18
-7.81% 1D
Market Cap $63.7M
1M Return +0.0%
1Y Return -91.26%
Forward P/E N/M
Unified AI Score
49.7 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 57.0 Mom 60.0
RXRX NASDAQ
Recursion Pharmaceuticals, Inc. Class A Common Stock
Biological Products, (No Disgnostic Substances)
$2.90
-8.79% 1D
Market Cap $2.1B
1M Return -16.16%
1Y Return -32.91%
Forward P/E N/M
Unified AI Score
49.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DGNX -91.26% RXRX -32.91% Spread: +58.35 pp (RXRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DGNX TTM Op. Margin: -546.3% RXRX TTM Op. Margin: -734.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DGNX vs RXRX. Trailing 12-month operating profitability (DGNX -546.3% vs RXRX -734.2%) and valuation multiples (DGNX N/M vs RXRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DGNX (2) vs RXRX (5)
Institutional Metric DGNX RXRX Criterion Row Winner
Market Capitalization Scale $63.7M $2.1B Larger Scale RXRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +3.3% +258.5% Higher Growth RXRX
Operating Margin (TTM) Profitability -546.3% -734.2% Higher Margin DGNX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -250.4% -48.7% Higher ROE RXRX
52-Week Range Position Momentum 4% ($0โ€“$18) 6% ($3โ€“$5) Stronger Trend RXRX
Beta / 30D Volatility Risk Regime 0.04ฮฒ ยท 100% Vol 3.01ฮฒ ยท 85% Vol Lower Realized Risk RXRX
Unified Institutional Score Composite Signal 49.7 / 100 (HOLD) 49.5 / 100 (HOLD) Higher Composite DGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DGNX vs RXRX Buy Guide
DGNX BREAKDOWN
140d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 51st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RXRX BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 61st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live RXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DGNX nor RXRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.